Article Text

Download PDFPDF
COVID-19 in patients with rheumatic diseases: what is the real mortality risk?
  1. Claudia Marques1,
  2. Marcelo M Pinheiro2,
  3. Edgard Torres Reis Neto2,
  4. Andrea Tavares Dantas1,
  5. Francinne Machado Ribeiro3,
  6. Ana Karla G Melo4
  1. 1 Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
  2. 2 Hospital São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil
  3. 3 Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
  4. 4 Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, Joao Pessoa, Brazil
  1. Correspondence to Dr Claudia Marques, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil; claudia.reumatologia{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the paper published by D’Silva et al 1 regarding the main outcomes in rheumatic patients with COVID-19. According to this cohort, there was a mortality rate of 6%, slightly similar to the frequency observed in individuals without rheumatic diseases (RDs) (around 4%). On the other hand, there was a threefold higher risk of intensive care admission and mechanical ventilation in patients with RDs, suggesting some difficulties to handle this subgroup. More recently, Favalli et al 2 stated that the incidence of COVID-19 was also quite similar between patients with RD and individuals from the general population in Lombardia (0.62% vs 0.66%, respectively). Moreover, the disease activity was not worsened or triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rheumatic patients.

Brazil had its first confirmed case of COVID-19 on 26 February, and, to date, it accounts for more than one million cases and more than 50 000 deaths. The lethality rate …

View Full Text


  • Collaborators Adriana Maria Kakehasi, Ana Paula Monteiro Gomides, Eduardo dos Santos Paiva, Gecilmara Cristina Salviato Pileggii, Gilda Aparecida Ferreira, Licia Maria Henrique da Mota, Ricardo Machado Xavier.

  • Contributors All authors have participated in the study to the conception or design of the work, or the acquisition, analysis or interpretation of cases; and subsequent revisions of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles